Tube Investments of India (TII) and Premji Invest (PI) on Saturday signed a share purchase agreement to acquire 100 per cent equity capital of Lotus Surgicals (Lotus) from India Medical Consumables Holdings (a Samara Capital entity) and other shareholders.
TII will acquire 67 per cent, while PI will acquire the remaining 33 per cent, subject to the completion of certain conditions. Currently, Lotus is engaged in the business of wound closure products.
TII will invest up to Rs 233 core and PI will invest up to Rs 115 crore to acquire equity shares from the existing shareholders of Lotus. TII is a part of the Chennai-based Murugappa group.
The acquisition is the first step for TII and PI to initiate a med-tech platform partnership. The platform aims to scale up through both organic growth and inorganic acquisitions. The platform draws inspiration from the vision of ‘Atmanirbhar Bharat’ and aspires to become a global platform to design, manufacture and distribute innovative world-class medical products at affordable price points.
M A M Arunachalam (also known as Arun Murugappan), executive chairman of TII, said, “The acquisition of Lotus marks our entry into the med-tech business. We believe that the Indian medical industry is expected to be one of the fastest-growing sectors driven by both demand and supply side factors. We are delighted to join hands with Premji Invest. Our deep expertise in establishing and managing large scale manufacturing, coupled with Premji Invest’s strong domain knowledge & investing experience will enable Lotus to tap the immense potential in the med-tech business.”
“TII has an outstanding track record of incubating and scaling businesses across diverse sectors and creating stakeholder value through manufacturing and execution excellence. Premji Invest is pleased to deepen its partnership with TII through this med-tech platform. We believe the medical consumables market is attractive, and there is a unique opportunity to create a global platform that manufactures and distributes world-class medical products by leveraging cutting-edge technologies,” said T K Kurien, chief investment officer, Premji Invest.
source
The post is published through a syndicated feed and attributed to Business Standard
